#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Alpha-1 antitrypsin deficiency Lip and/or oral cavity cancer Adult T-cell lymphoma/leukaemia refractory Non-small cell lung cancer Crigler-Najjar syndrome Becker's muscular dystrophy Rhabdoid tumour Bulbospinal muscular atrophy congenital Hydrocephalus Neuroendocrine tumour of the lung Angiosarcoma non-metastatic Marginal zone lymphoma refractory Thrombotic microangiopathy Lymphatic malformation Restless legs syndrome More trials…

    Learn about Rare Diseases

    Pleomorphic leiomyosarcoma – Diagnostics Kearns-Sayre syndrome – Basic Information Mantle cell lymphoma refractory Behcet’s syndrome – Trials in Disease Kearns-Sayre syndrome – Treatment Inclusion body myositis – Treatment Medulloblastoma – Diagnostics Ewing’s sarcoma – Diagnostics Adrenogenital syndrome – Basic Information Osteosarcoma recurrent More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Hydroxypropyl Cellulose Lf Interferon Beta-1A Diclofenac Pirtobrutinib Nepafenac Mk-1084 Pyridoxine Hydrochloride Bp Bemarituzumab Bi 765845 Protein C Clascoterone Chlorpromazine Hydrochloride Ketoprofen ABY-271 Fluorouracil Bp1.7881A Oxytocin Ly3454738 Atezolizumab ARLOCABTAGENE AUTOLEUCEL More therapies…

    Learn about Your Condition

    Chronic sinusitis Colorectal cancer Lichenoid keratosis Liver transplant rejection ROHHAD syndrome Mental disorder Urticaria chronic Prolymphocytic leukaemia Inner ear disorder HER2 positive breast cancer Affective disorder Primary amyloidosis Palpitations Tonsillitis Essential hypertension More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centre Oscar Lambret

Centre Oscar Lambret

3 Rue Frederic Combemale, Lille, 59000, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Reducing Treatment for Stage IIa/IIb Seminoma Using Etoposide, Cisplatin, and Carboplatin in Patients with Tumors Smaller than 3 cm

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Etoposide
    France

  • Study of avelumab and cetuximab combination treatment after TPEx chemotherapy for patients with recurrent or metastatic head and neck cancer receiving first-line therapy

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • Avelumab
    • Carboplatin
    • Cetuximab
    France

  • Study on Ependymoma Treatment in Children, Adolescents, and Young Adults Using Cisplatin, Cyclophosphamide, Etoposide, and a Drug Combination

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Ependymoma
    Investigated Drugs:
    • Sodium Valproate
    • Cisplatin
    • Cyclophosphamide
    Austria Belgium Czechia Denmark Finland France +7

  • Study of Capecitabine and Pembrolizumab for Patients with Triple Negative Breast Cancer After Chemoimmunotherapy and Surgery

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Capecitabine
    • Pembrolizumab
    France

  • Study of drug combinations including irinotecan, ifosfamide, vincristine, dactinomycin, regorafenib and other agents for children and adults with rhabdomyosarcoma

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Rhabdomyosarcoma
    Investigated Drugs:
    • Dactinomycin
    • Temozolomide
    • Vinorelbine Tartrate
    Austria Belgium Czechia Denmark Finland France +10

  • Study on the Effectiveness of Cemiplimab and Drug Combination for Patients with Oligometastatic Non-Small Cell Lung Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Tremelimumab
    • Atezolizumab
    • Carboplatin
    France

  • Study on Zanidatamab and Chemotherapy for Patients with Metastatic HER2-Positive Breast Cancer After Trastuzumab Deruxtecan Treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    • Breast cancer
    Investigated Drugs:
    • Eribulin Mesylate
    • Capecitabine
    • Gemcitabine Hydrochloride
    Austria Belgium France Germany Greece Italy +2

  • Chemotherapy Dose Adjustment for Gastrointestinal Cancer Patients with DPD Deficiency Using Fluorouracil, Capecitabine, and Oxaliplatin

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Gastrointestinal cancer metastatic
    Investigated Drugs:
    • Capecitabine
    • Fluorouracil
    • Folinic Acid
    France

  • Study on High-Risk Neuroblastoma Treatment with Busulfan, Melphalan, and Drug Combination for Patients with Insufficient Metastatic Response

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Busulfan
    • Dinutuximab Beta
    • Melphalan
    Austria Belgium Czechia Denmark Finland France +13

  • Study on the Effects of ZN-c3 for Patients with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Fallopian tube cancer
    • Malignant peritoneal neoplasm
    • Ovarian cancer
    Investigated Drugs:
    • Aprepitant
    • Azenosertib
    • Betamethasone Sodium Phosphate Ph. Eur
    Belgium France Italy Poland Spain
Previous Page
1 … 5 6 7 8 9 … 26
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!